{"Title": "SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection", "Year": 2018, "Source": "Lancet Diabetes Endocrinol.", "Volume": "6", "Issue": 6, "Art.No": null, "PageStart": 435, "PageEnd": 437, "CitedBy": 25, "DOI": "10.1016/S2213-8587(17)30314-5", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85030848386&origin=inward", "Abstract": null, "AuthorKeywords": null, "IndexKeywords": ["Benzhydryl Compounds", "Canagliflozin", "Cardiovascular Diseases", "Clinical Trials as Topic", "Diabetes Complications", "Glucosides", "Humans", "Hypoglycemic Agents", "Sodium-Glucose Transporter 2 Inhibitors", "Treatment Outcome"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 2, "EID": "2-s2.0-85030848386", "SubjectAreas": [["Internal Medicine", "MEDI", "2724"], ["Endocrinology, Diabetes and Metabolism", "MEDI", "2712"], ["Endocrinology", "BIOC", "1310"]], "AuthorData": {"57213808377": {"Name": "Bell R.", "AuthorID": "57213808377", "AffiliationID": "60022148", "AffiliationName": "The Hatter Cardiovascular Institute, University College London"}, "7103223278": {"Name": "Yellon D.", "AuthorID": "7103223278", "AffiliationID": "60022148", "AffiliationName": "The Hatter Cardiovascular Institute, University College London"}}}